Florian Franz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/554374/publications.pdf

Version: 2024-02-01

471061 676716 22 930 17 22 citations h-index g-index papers 22 22 22 776 docs citations all docs times ranked citing authors

#	Article	IF	CITATIONS
1	Detection and phase I metabolism of the 7â€azaindoleâ€derived synthetic cannabinoid 5Fâ€ABâ€P7AICA including a preliminary pharmacokinetic evaluation. Drug Testing and Analysis, 2020, 12, 78-91.	1.6	21
2	Extraordinary long detection window of a synthetic cannabinoid metabolite in human urine – Potential impact on therapeutic decisions. Drug Testing and Analysis, 2020, 12, 391-396.	1.6	10
3	Phase I metabolic profiling of the synthetic cannabinoids THJ-018 and THJ-2201 in human urine in comparison to human liver microsome and cytochrome P450 isoenzyme incubation. International Journal of Legal Medicine, 2019, 133, 1049-1064.	1.2	8
4	Structure-metabolism relationships of valine and tert-leucine-derived synthetic cannabinoid receptor agonists: a systematic comparison of the in vitro phase I metabolism using pooled human liver microsomes and high-resolution mass spectrometry. Forensic Toxicology, 2019, 37, 316-329.	1.4	24
5	5F-Cumyl-PINACA in â€e-liquids' for electronic cigarettes: comprehensive characterization of a new type of synthetic cannabinoid in a trendy product including investigations on the in vitro and in vivo phase I metabolism of 5F-Cumyl-PINACA and its non-fluorinated analog Cumyl-PINACA. Forensic Toxicology, 2019, 37, 186-196.	1.4	28
6	Human phase I metabolism of the novel synthetic cannabinoid 5F-CUMYL-PEGACLONE. Forensic Toxicology, 2019, 37, 154-163.	1.4	17
7	Synthetic cannabinoids in hair – Pragmatic approach for method updates, compound prevalences and concentration ranges in authentic hair samples. Analytica Chimica Acta, 2018, 1006, 61-73.	2.6	30
8	Phase I metabolism of the recently emerged synthetic cannabinoid CUMYLâ€PEGACLONE and detection in human urine samples. Drug Testing and Analysis, 2018, 10, 886-891.	1.6	28
9	Phase I metabolism of the carbazoleâ€derived synthetic cannabinoids EGâ€018, EGâ€2201, and MDMBâ€CHMCZG and detection in human urine samples. Drug Testing and Analysis, 2018, 10, 1417-1429.	CA 1.6	15
10	Detection of the recently emerged synthetic cannabinoid 5F–MDMBâ€PICA in â€~legal high' products and human urine samples. Drug Testing and Analysis, 2018, 10, 196-205.	1.6	78
11	Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. Clinical Toxicology, 2018, 56, 404-411.	0.8	46
12	Metabolism of Nine Synthetic Cannabinoid Receptor Agonists Encountered in Clinical Casework: Major in vivo Phase I Metabolites of AM-694, AM-2201, JWH-007, JWH-019, JWH-203, JWH-307, MAM-2201, UR-144 and XLR-11 in Human Urine Using LC-MS/MS. Current Pharmaceutical Biotechnology, 2018, 19, 144-162.	0.9	14
13	<i>In vitro</i> metabolism of the synthetic cannabinoid 3,5â€ABâ€CHMFUPPYCA and its 5,3â€regioisomer and investigation of their thermal stability. Drug Testing and Analysis, 2017, 9, 311-316.	1.6	19
14	Immunoassay screening in urine for synthetic cannabinoids $\hat{a}\in$ an evaluation of the diagnostic efficiency. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1375-1384.	1.4	46
15	Activity-Based Detection of Consumption of Synthetic Cannabinoids in Authentic Urine Samples Using a Stable Cannabinoid Reporter System. Analytical Chemistry, 2017, 89, 9527-9536.	3.2	81
16	Phase I metabolism of the highly potent synthetic cannabinoid MDMBâ€CHMICA and detection in human urine samples. Drug Testing and Analysis, 2017, 9, 744-753.	1.6	54
17	Metabolites of synthetic cannabinoids in hairâ€"proof of consumption or false friends for interpretation?. Analytical and Bioanalytical Chemistry, 2016, 408, 3445-3452.	1.9	45
18	Characterization and <i>in vitro</i> phase I microsomal metabolism of designer benzodiazepines — an update comprising adinazolam, cloniprazepam, fonazepam, 3â€hydroxyphenazepam, metizolam and nitrazolam. Journal of Mass Spectrometry, 2016, 51, 1080-1089.	0.7	38

#	Article	IF	CITATIONS
19	Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites with a Newly Developed Bioassay. Analytical Chemistry, 2016, 88, 11476-11485.	3.2	193
20	Adverse effects after the use of JWHâ€210 – a case series from the EU Spice II plus project. Drug Testing and Analysis, 2016, 8, 1030-1038.	1.6	47
21	Reply to â€~Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA'. Journal of Analytical Toxicology, 2016, 40, 240-242.	1.7	30
22	Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites. Forensic Toxicology, 2015, 33, 388-395.	1.4	58